Research programme: immunosuppressive therapeutics - Abbott Laboratories

Drug Profile

Research programme: immunosuppressive therapeutics - Abbott Laboratories

Alternative Names: A 420983; A-770041; Immunosuppressive therapeutics research programme - Abbott Laboratories; Lck inhibitors - Abbott Laboratories

Latest Information Update: 24 Jan 2013

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Class Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Transplant rejection

Most Recent Events

  • 24 Jan 2013 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)
  • 19 May 2004 Data presented at the American Transplant Congress 2004 (ATC-2004) have been added to the Transplant rejection pharmacodynamics section
  • 16 Sep 2002 Preclinical trials in Transplant rejection in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top